Coexistence of t(2;14;11)(p16.1;q32;q23) and t(14;19)(q32;q13.3) chromosome translocations in a patient with chronic lymphocytic leukemia

Abstract

Rationale:With combination of multiple techniques, we have successfully characterized unique, complex chromosomal changes in a patient with chronic lymphocytic leukemia (CLL), a lymphoproliferative disorder.Diagnoses:The diagnosis was based on white blood cell, flow cytometry, and immunophenotypes and confirmed by karyotype, fluorescence in situ hybridization, and array comparative genomic hybridization from the patient's blood culture.Interventions:The patient was given fludarabine, cyclophosphamide and rituximab (FCR) for 6 cycles.Outcomes:After completion of 6 cycles of FCR, the computed tomography scans of the neck/chest/abdomen/pelvic showed that the patient in CR. During the 10-month follow-up, the patient's clinical course remained uneventful.Lessons:The translocation t(14;19) identified in this patient is a recurrent translocation found in patients with chronic B-cell lymphoproliferative disorders and the 3-way translocation involving chromosomes 2, 14, and 11 may play a role as an enhancer.

Demographic data in patients with Chronic Lymphocytic Leukemia

“…Chronic lymphocytic leukemia is a heterogeneous group of clonal neoplastic pathologies characterized by the proliferation of mature B or T lymphoid cells (Carbone and Gloghini, 2017). Chronic lymphatic leukemia (CLL) is a neoplastic disease characterized by a monoclonal proliferation of slow-division, immunelogically incompetent B cells that mature in the bone marrow, lymph nodes and peripheral blood (Liu et al, 2017) Several prognostic markers are used for this prognostic importance and indicate CLL prognostic index such as: Binet and RAI staging of CLL patients (Wu et al, 2019). Some studies found the presence of smudge cell in peripheral blood of CLL patients.…”